Clinical and Endoscopic Evaluations of Sessile Serrated Adenoma/polyps with Cytological Dysplasia
Overview
Authors
Affiliations
Background And Aim: Although sessile serrated adenoma/polyps (SSA/Ps) are considered to be premalignant lesions and rapidly progress to carcinomas after they develop cytological dysplasia (CD), a treatment strategy for SSA/Ps in Asian countries is still being debated and has not yet been established. The present study aimed to propose a treatment strategy for SSA/Ps.
Methods: Histopathological data of patients, who underwent colonoscopy at our center between January 2011 and December 2016, were reviewed. Data of patients with ≥ 1 SSA/P were retrieved, and clinicopathological characteristics were retrospectively analyzed.
Results: A total of 281 patients with 326 SSA/Ps, including 258 patients who had 300 SSA/Ps without CD (SSA/Ps-CD[-]) and 23 patients who had 26 SSA/Ps with CD (SSA/Ps-CD[+]), were evaluated in this study. Although SSA/Ps-CD(+) were often found in older female patients and in the proximal colon, there were no significant differences between SSA/Ps-CD(-) and SSA/Ps-CD(+). Endoscopic morphological findings, such as large or small nodules on the surface and partial protrusion of the lesions, were significantly more common in SSA/Ps-CD(+) than in SSA/Ps-CD(-). Although the diagnostic ability of nodule/protrusion in lesions to predict CD within SSA/Ps was very high with an accuracy of 93.9% and a negative predictive value of 95.4%, sensitivity was low at 46.2%. SSA/Ps-CD(+) were significantly larger than SSA/Ps-CD(-), and the rate of CD within SSA/Ps significantly increased with lesion size (≤ 5 mm, 0%; 6-9 mm, 6.0%; ≥ 10 mm, 13.6%).
Conclusion: The study proposes removing all SSA/Ps ≥ 6 mm in order to remove high-risk SSA/Ps-CD(+), with high sensitivity.
Lamba M, Brown I, Bettington M, Ryan K, Hanigan K, Lasenby K Gastro Hep Adv. 2024; 1(3):313-320.
PMID: 39131677 PMC: 11308794. DOI: 10.1016/j.gastha.2021.12.010.
Kobayashi R, Yoshida N, Morinaga Y, Hashimoto H, Tomita Y, Sugino S Gastroenterol Res Pract. 2024; 2024:2672289.
PMID: 38882393 PMC: 11178415. DOI: 10.1155/2024/2672289.
Wang R, Ren Y, Jiang X, Wei L, Zhang X, Liu H World J Clin Cases. 2023; 11(29):6995-7003.
PMID: 37946753 PMC: 10631427. DOI: 10.12998/wjcc.v11.i29.6995.
Sessile serrated lesions with dysplasia: is it possible to nip them in the bud?.
Utsumi T, Yamada Y, Diaz-Meco M, Moscat J, Nakanishi Y J Gastroenterol. 2023; 58(8):705-717.
PMID: 37219625 PMC: 10366009. DOI: 10.1007/s00535-023-02003-9.
Clinical and endoscopic characteristics of sessile serrated lesions with dysplasia/carcinoma.
Jung P, Kim H, Park S, Kang D, Choi C, Kim S Korean J Intern Med. 2023; 38(3):349-361.
PMID: 36967594 PMC: 10175875. DOI: 10.3904/kjim.2022.322.